Which patients should be considered for gene therapy

Area of Science:

• Hematology
• Gene Therapy
• Viral Vector Technology

Background:

• Gene therapy utilizing adeno-associated viral vectors (AAVs) and coagulation factor genes has shown significant promise for treating hemophilia.
• Recent approvals mark the introduction of the first gene therapy products into clinical practice, necessitating a thorough understanding of their application.

Purpose of the Study:

• To outline the critical inclusion and exclusion criteria for gene therapy in hemophilia patients.
• To emphasize the importance of understanding the treatment process, associated risks, and the need for long-term safety and efficacy evaluation.
• To highlight the evolving landscape of gene therapy accessibility and the continuous assessment of patient eligibility for AAV-based treatments.

Main Methods:

• Review of current gene therapy protocols for hemophilia.
• Evaluation of patient-specific factors influencing treatment success, including liver condition, anti-AAV status, and medical history.
• Assessment of patient motivation, willingness to adhere to monitoring and potential immunosuppression, and engagement in shared decision-making.

Main Results:

• Predefined inclusion and exclusion criteria are essential for safe and effective gene therapy.
• Thorough patient evaluation, including liver health and immune status, is critical for optimizing outcomes.
• Patient engagement and adherence to treatment protocols significantly impact gene therapy success.

Conclusions:

• Gene therapy for hemophilia requires careful patient selection and comprehensive long-term monitoring.
• Factors beyond established criteria, such as patient commitment, influence treatment efficacy.
• Ongoing data collection may lead to expanded inclusion criteria, increasing patient access to AAV-based gene therapies.